The long-term follow-up of patients with thionamidetreated graves’ hyperthyroidism

Sachiko Bandai, Ken Okamura, Megumi Fujikawa, Kaori Sato, Hiroshi Ikenoue, Takanari Kitazono

Research output: Contribution to journalArticle

Abstract

Since there have been few reports on the long-term prognosis of Graves’ hyperthyroidism, the prognosis of 549 Graves’ hyperthyroidism patients initially treated with thionamide and followed for >8 (range: 8.6-36.4) years was studied, evaluating the change in the TSH binding inhibitor immunoglobulin activity (TBII). The distribution of the time required for the first disappearance of TBII was normal after logarithmic conversion, and the mean ± 2 SD was 1.5 (0.3-8.1) years. TBII became negative once within 5 years in 78.9% of patients. However, TBII re-elevation was observed in 47.8% of this group (fluctuating type). Remission was observed in 88.9% of the non-fluctuating type (smooth remission) and 37.2% of the fluctuating type patients. TBII remained positive for >5 years in 21.1% (smoldering type) of patients, with remission observed in only 19.8% of patients. Final remission was observed in 301 (54.8%) patients; the median time to remission was 6.8 (interquartile range: 4.0-10.9) years. A longer time until normalization of TBII and higher final thyroid weight were associated with a poor prognosis. Spontaneous hypothyroidism was observed in 6.0% of patients, independent of the TBII change. Our findings suggest that remission of Graves’ hyperthyroidism mostly occurred after 4-11 years treatment. While predicting the prognosis before therapy was difficult, the clinical course may suggest a better prognosis if TBII disappears within five years without TBII fluctuation or enlargement of the goiter. Patients may safely wait more than five years to undergo ablative therapy if they hope to avoid permanent hypothyroidism.

Original languageEnglish
Pages (from-to)535-545
Number of pages11
JournalEndocrine Journal
Volume66
Issue number6
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Hyperthyroidism
Immunoglobulins
Hypothyroidism
Goiter
Thyroid Gland
Therapeutics
Weights and Measures

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

The long-term follow-up of patients with thionamidetreated graves’ hyperthyroidism. / Bandai, Sachiko; Okamura, Ken; Fujikawa, Megumi; Sato, Kaori; Ikenoue, Hiroshi; Kitazono, Takanari.

In: Endocrine Journal, Vol. 66, No. 6, 01.01.2019, p. 535-545.

Research output: Contribution to journalArticle

Bandai, Sachiko ; Okamura, Ken ; Fujikawa, Megumi ; Sato, Kaori ; Ikenoue, Hiroshi ; Kitazono, Takanari. / The long-term follow-up of patients with thionamidetreated graves’ hyperthyroidism. In: Endocrine Journal. 2019 ; Vol. 66, No. 6. pp. 535-545.
@article{dc6ed10a06ee48b19180845826926473,
title = "The long-term follow-up of patients with thionamidetreated graves’ hyperthyroidism",
abstract = "Since there have been few reports on the long-term prognosis of Graves’ hyperthyroidism, the prognosis of 549 Graves’ hyperthyroidism patients initially treated with thionamide and followed for >8 (range: 8.6-36.4) years was studied, evaluating the change in the TSH binding inhibitor immunoglobulin activity (TBII). The distribution of the time required for the first disappearance of TBII was normal after logarithmic conversion, and the mean ± 2 SD was 1.5 (0.3-8.1) years. TBII became negative once within 5 years in 78.9{\%} of patients. However, TBII re-elevation was observed in 47.8{\%} of this group (fluctuating type). Remission was observed in 88.9{\%} of the non-fluctuating type (smooth remission) and 37.2{\%} of the fluctuating type patients. TBII remained positive for >5 years in 21.1{\%} (smoldering type) of patients, with remission observed in only 19.8{\%} of patients. Final remission was observed in 301 (54.8{\%}) patients; the median time to remission was 6.8 (interquartile range: 4.0-10.9) years. A longer time until normalization of TBII and higher final thyroid weight were associated with a poor prognosis. Spontaneous hypothyroidism was observed in 6.0{\%} of patients, independent of the TBII change. Our findings suggest that remission of Graves’ hyperthyroidism mostly occurred after 4-11 years treatment. While predicting the prognosis before therapy was difficult, the clinical course may suggest a better prognosis if TBII disappears within five years without TBII fluctuation or enlargement of the goiter. Patients may safely wait more than five years to undergo ablative therapy if they hope to avoid permanent hypothyroidism.",
author = "Sachiko Bandai and Ken Okamura and Megumi Fujikawa and Kaori Sato and Hiroshi Ikenoue and Takanari Kitazono",
year = "2019",
month = "1",
day = "1",
doi = "10.1507/endocrj.EJ18-0418",
language = "English",
volume = "66",
pages = "535--545",
journal = "Endocrine Journal",
issn = "0918-8959",
publisher = "Japan Endocrine Society",
number = "6",

}

TY - JOUR

T1 - The long-term follow-up of patients with thionamidetreated graves’ hyperthyroidism

AU - Bandai, Sachiko

AU - Okamura, Ken

AU - Fujikawa, Megumi

AU - Sato, Kaori

AU - Ikenoue, Hiroshi

AU - Kitazono, Takanari

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Since there have been few reports on the long-term prognosis of Graves’ hyperthyroidism, the prognosis of 549 Graves’ hyperthyroidism patients initially treated with thionamide and followed for >8 (range: 8.6-36.4) years was studied, evaluating the change in the TSH binding inhibitor immunoglobulin activity (TBII). The distribution of the time required for the first disappearance of TBII was normal after logarithmic conversion, and the mean ± 2 SD was 1.5 (0.3-8.1) years. TBII became negative once within 5 years in 78.9% of patients. However, TBII re-elevation was observed in 47.8% of this group (fluctuating type). Remission was observed in 88.9% of the non-fluctuating type (smooth remission) and 37.2% of the fluctuating type patients. TBII remained positive for >5 years in 21.1% (smoldering type) of patients, with remission observed in only 19.8% of patients. Final remission was observed in 301 (54.8%) patients; the median time to remission was 6.8 (interquartile range: 4.0-10.9) years. A longer time until normalization of TBII and higher final thyroid weight were associated with a poor prognosis. Spontaneous hypothyroidism was observed in 6.0% of patients, independent of the TBII change. Our findings suggest that remission of Graves’ hyperthyroidism mostly occurred after 4-11 years treatment. While predicting the prognosis before therapy was difficult, the clinical course may suggest a better prognosis if TBII disappears within five years without TBII fluctuation or enlargement of the goiter. Patients may safely wait more than five years to undergo ablative therapy if they hope to avoid permanent hypothyroidism.

AB - Since there have been few reports on the long-term prognosis of Graves’ hyperthyroidism, the prognosis of 549 Graves’ hyperthyroidism patients initially treated with thionamide and followed for >8 (range: 8.6-36.4) years was studied, evaluating the change in the TSH binding inhibitor immunoglobulin activity (TBII). The distribution of the time required for the first disappearance of TBII was normal after logarithmic conversion, and the mean ± 2 SD was 1.5 (0.3-8.1) years. TBII became negative once within 5 years in 78.9% of patients. However, TBII re-elevation was observed in 47.8% of this group (fluctuating type). Remission was observed in 88.9% of the non-fluctuating type (smooth remission) and 37.2% of the fluctuating type patients. TBII remained positive for >5 years in 21.1% (smoldering type) of patients, with remission observed in only 19.8% of patients. Final remission was observed in 301 (54.8%) patients; the median time to remission was 6.8 (interquartile range: 4.0-10.9) years. A longer time until normalization of TBII and higher final thyroid weight were associated with a poor prognosis. Spontaneous hypothyroidism was observed in 6.0% of patients, independent of the TBII change. Our findings suggest that remission of Graves’ hyperthyroidism mostly occurred after 4-11 years treatment. While predicting the prognosis before therapy was difficult, the clinical course may suggest a better prognosis if TBII disappears within five years without TBII fluctuation or enlargement of the goiter. Patients may safely wait more than five years to undergo ablative therapy if they hope to avoid permanent hypothyroidism.

UR - http://www.scopus.com/inward/record.url?scp=85069237066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069237066&partnerID=8YFLogxK

U2 - 10.1507/endocrj.EJ18-0418

DO - 10.1507/endocrj.EJ18-0418

M3 - Article

C2 - 30918165

AN - SCOPUS:85069237066

VL - 66

SP - 535

EP - 545

JO - Endocrine Journal

JF - Endocrine Journal

SN - 0918-8959

IS - 6

ER -